Appointment of Parag Mallick to Scientific Board

RNS Number : 7601U

Oncimmune Holdings PLC

02 April 2019

 

2 April 2019

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Oncimmune appoints Dr Parag Mallick to Scientific Board

Oncimmune Holdings plc (AIM: ONC.L), a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer, today announces the appointment of Dr. Parag Mallick to its Scientific Board.

Dr Parag Mallick is an Associate Professor of Radiology at Stanford University. He is a member of the Canary Center for Cancer Early Detection. Originally trained as an engineer and biochemist, his research spans computational and experimental systems biology, cancer biology and nanotechnology. He received his BS in Computer Science and Biochemistry at Washington University in St. Louis and then went onto complete his doctoral studies with David Eisenberg at UCLA. After his PhD, he trained with Prof Dr Ruedi Aebersold in clinical proteomics and systems biology at the Institute for Systems Biology.

Dr Mallick's research at the Mallick Lab is focused on pioneering approaches for using big data, mathematical modelling and machine learning to discover cancer biomarkers and enable personalised and predictive medicine.

Dr Adam M Hill, CEO of Oncimmune commented: "Parag's work is prodigious in the field of the early detection of cancer using a number of complementary tools and processes. His mission and expertise will be invaluable to Oncimmune as we continue to develop our immunogenic protein platform and high throughput discovery approach, as well as consider the value of contextual data in clinical testing."

Professor Peter Johnston, Chair of the Scientific Board commented: "I'm pleased to welcome Parag as the latest member of Oncimmune's Scientific Board. Oncimmune has assembled a team of high quality individuals who all share Oncimmune's belief that early detection is the key to beating cancer and helping healthcare systems cope with the burdens of many diseases. The calibre of the individuals participating on this Scientific Board is an excellent validation of the potential of Oncimmune's immunogenic protein platform and we are excited by what Oncimmune can achieve in the next three years and beyond."

Dr Parag Mallick commented: "I believe the future of early cancer detection lies in the identification of biomarkers which can not only be used to detect cancers earlier, but also to describe how they are likely to behave. Whilst there are thousands of publications highlighting putative candidates, very few biomarkers are being used clinically. Oncimmune has already developed a panel of biomarkers for the early detection of lung cancer and liver cancer and I am looking forward to working closely with the other Scientific Board members and the Company as it embarks on its next stage of growth."

-Ends-

For further information:

Oncimmune Holdings plc

Adam Hill, Chief Executive Officer

[e-mail]

Zeus Capital Limited (Nominated Adviser and Joint Broker)

Andrew Jones, Mike Seabrook

[phone]

Bryan, Garnier & Co Limited (Joint Broker)

Phil Walker, Dominic Wilson

[phone]

Media enquiries:

Consilium Strategic Communications

Chris Gardner, Matthew Neal, Lindsey Neville

[e-mail]

[phone]

About Oncimmune

Beating cancer, one test at a time 

Oncimmune is a leader in the development, manufacture and commercialisation of cancer specific immunodiagnostics for the screening, detection and care of cancer. Oncimmune also develops precision medicine and patient stratification tools for leading pharmaceutical multinationals in both immuno-oncology and autoimmune disease. Oncimmune is working to change how cancer is diagnosed and treated. Its patented technology detects evidence of the body's natural response to cancer, enabling detection four years or more before standard clinical diagnosis. Oncimmune's tests facilitate clinical decision-making and are complementary to diagnostic technologies, making them valuable additions to established and new care pathways. Oncimmune partners with leading developers and distributors to make our technology available globally. 

Oncimmune was founded in 2002 and launched its platform technology in 2009, followed by its first commercial tests, EarlyCDT-Lung and EarlyCDT-Liver. To date, over 155,000 tests have been performed for patients worldwide and EarlyCDT-Lung is being used in the largest-ever randomised trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) ECLS study of 12,210 high-risk smokers in Scotland. Oncimmune, headquartered at its laboratory facility in Nottingham, UK, has a discovery research centre in Dortmund, Germany and a CLIA lab in Kansas, US as well as offices in London, UK and Shanghai, China. Oncimmune joined the Alternative Investment Market (AIM) of the London Stock Exchange in May 2016 under the ticker ONC.L.

For more information, visit www.oncimmune.com

 

END

 

 

MSCUGUBWCUPBPUG